pioglitazone has been researched along with MS (Multiple Sclerosis) in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 5.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 1.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negrotto, L | 1 |
| Farez, MF | 1 |
| Correale, J | 1 |
| Feinstein, DL | 2 |
| Galea, E | 1 |
| Gavrilyuk, V | 1 |
| Brosnan, CF | 1 |
| Whitacre, CC | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Landreth, GE | 1 |
| Pershadsingh, HA | 1 |
| Weinberg, G | 1 |
| Heneka, MT | 3 |
| Schmidt, S | 1 |
| Moric, E | 1 |
| Schmidt, M | 2 |
| Sastre, M | 2 |
| Klotz, L | 1 |
| Giese, T | 1 |
| Knolle, P | 1 |
| Klockgether, T | 1 |
| Peiris, M | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Cabot, PJ | 1 |
| Niino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177] | Phase 1 | 30 participants | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl | 2007 |
5 other studies available for pioglitazone and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Topics: Adipokines; Anti-Inflammatory Agents; Brain; Cohort Studies; Cytokines; Disability Evaluation; Dose- | 2016 |
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimen | 2002 |
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cell Divi | 2004 |
Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Diabetes Mellitus, Type 2; DNA; Fem | 2005 |
A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
Topics: Adjuvants, Immunologic; Animals; Central Nervous System; Chemotaxis, Leukocyte; Disability Evaluatio | 2007 |